Evidence map›Paper›PMID 34484435›Full record

ArticleNano LIFE2021

Intratumoral Photosensitizer Delivery and Photodynamic Therapy.

Chen-Hua Ma, Jeffrey Yang, Jenna L Mueller, Huang-Chiao Huang

Open access · greenAbstract read
In one paragraph

Article in Nano LIFE, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Towards chlorocytes for therapeutic intravascular photosynthesis.Applied microbiology and biotechnology · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Chen-Hua MaFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Jeffrey YangFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Jenna L MuellerFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Huang-Chiao HuangFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
University of Maryland, College Park · US

Funding

Addressing Chemoresistance in Pancreatic and Ovarian Cancers: Photodynamic Priming and Repurposing of Tetracyclines using Targeted Photo-Activable Multi-Inhibitor LiposomeR01CA260340 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HUANG, HUANG CHIAO · 2021 to 2025
$3.2M
Photodynamic Priming for Bidirectional Modulation of Drug Transport Across the Blood-Brain Tumor BarrierR21EB028508 · NIBIB · UNIV OF MARYLAND, COLLEGE PARK · PI HUANG, HUANG CHIAO · 2020 to 2022
$621k
NCI NIH HHS R01 CA260340NIBIB NIH HHS R21 EB028508
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a two-step procedure that involves the administration of special drugs, commonly called photosensitizers, followed by the application of certain wavelengths of light. The light activates these photosensitizers to produce reactive molecular species that induce cell death in tissues. There are numerous factors to consider when selecting the appropriate photosensitizer administration route, such as which part of the body is being targeted, the pharmacokinetics of photosensitizers, and the formulation of photosensitizers. While intravenous, topical, and oral administration of photosensitizers are widely used in preclinical and clinical applications of PDT, other administration routes, such as intraperitoneal, intra-arterial, and intratumoral injections, are gaining traction for their potential in treating advanced diseases and reducing off-target toxicities. With recent advances in targeted nanotechnology, biomaterials, and light delivery systems, the exciting possibilities of targeted photosensitizer delivery can be fully realized for preclinical and clinical applications. Further, in light of the growing burden of cancer mortality in low and middle-income countries and development of low-cost light sources and photosensitizers, PDT could be used to treat cancer patients in low-income settings. This short article introduces aspects of interfaces of intratumoral photosensitizer injections and nano-biomaterials for PDT applications in both high-income and low-income settings but does not present a comprehensive review due to space limitations.

Identifiers

PMID34484435
PMCPMC8412167
OpenAlexW3165960698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.